Radioactive microspheres show promise in early liver cancer trial
NCT ID NCT06310590
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 1 trial tested a new injection called NRT6003, which contains tiny radioactive beads (yttrium-90), in 40 people with liver cancer that could not be removed by surgery. The goal was to see if the treatment is safe and whether it can shrink tumors in the liver. Researchers measured side effects and how long it took for the cancer to progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 carbon microspheres (NRT6003 injection)
What this could lead to
If it works, this could offer a new radiation treatment option for people with liver cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase (Phase 1) trial with only 40 participants, so results may not apply broadly. The treatment involves radiation and could cause side effects like liver damage or other adverse events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Hunan Provincial People's Hospital
Changsha, Hunan, China
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
-
Zhongshan Hospital, Fudan University
Shanghai, China